Experimental cell therapy aims to boost immune system against Hard-to-Treat prostate cancer

NCT ID NCT06056791

Completed Disease control Sponsor: Inmune Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested an experimental cell therapy called INKmune in 12 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to find the safest and most effective dose by measuring immune cell activity, PSA levels, and tumor changes. The treatment is given as three intravenous doses, and the study focused on safety and signs of disease control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer castration-resistant prostate carcinoma metastatic prostate carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER MCRPC METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Carl & Edyth Lindner Center for Research and Education at The Christ Hospital and The Christ Hospital Cancer Center

Cincinnati, Ohio, 45219, United States
Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, 89169, United States
NEXT Virginia

Fairfax, Virginia, 22031, United States
Renovatio Clinical

El Paso, Texas, 79915, United States
Renovatio Clinical

The Woodlands, Texas, 77380, United States
University of California, Los Angeles

Los Angeles, California, 90095, United States
VA Greater Los Angeles Healthcare System

Los Angeles, California, 90073, United States
VA Puget Sound Health Care System

Seattle, Washington, 98108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.